1. Home
  2. PRE vs ACIU Comparison

PRE vs ACIU Comparison

Compare PRE & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prenetics Global Limited

PRE

Prenetics Global Limited

HOLD

Current Price

$19.86

Market Cap

295.3M

Sector

Industrials

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.25

Market Cap

288.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRE
ACIU
Founded
2014
2003
Country
Hong Kong
Switzerland
Employees
285
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
295.3M
288.0M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
PRE
ACIU
Price
$19.86
$2.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$30.50
$10.00
AVG Volume (30 Days)
277.9K
266.5K
Earning Date
06-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$108.69
$706.75
Revenue Next Year
$58.68
$321.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.88
$1.65
52 Week High
$23.63
$4.00

Technical Indicators

Market Signals
Indicator
PRE
ACIU
Relative Strength Index (RSI) 57.45 24.95
Support Level $12.92 $2.03
Resistance Level $21.72 $3.92
Average True Range (ATR) 1.66 0.17
MACD 0.45 -0.06
Stochastic Oscillator 73.33 3.06

Price Performance

Historical Comparison
PRE
ACIU

About PRE Prenetics Global Limited

Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: